Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.816 EUR -1.4%
Market Cap: 656.2m EUR

Valneva SE
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Valneva SE
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Cash & Cash Equivalents
€161.3m
CAGR 3-Years
-22%
CAGR 5-Years
-3%
CAGR 10-Years
14%
Nanobiotix SA
PAR:NANO
Cash & Cash Equivalents
€28.8m
CAGR 3-Years
-23%
CAGR 5-Years
11%
CAGR 10-Years
2%
Inventiva SA
PAR:IVA
Cash & Cash Equivalents
€96.6m
CAGR 3-Years
8%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Cash & Cash Equivalents
$59.8m
CAGR 3-Years
-20%
CAGR 5-Years
-28%
CAGR 10-Years
-7%
DBV Technologies SA
PAR:DBV
Cash & Cash Equivalents
$103.2m
CAGR 3-Years
-25%
CAGR 5-Years
-15%
CAGR 10-Years
0%
Eurobio Scientific SA
PAR:ALERS
Cash & Cash Equivalents
€26.9m
CAGR 3-Years
-38%
CAGR 5-Years
10%
CAGR 10-Years
9%
No Stocks Found

Valneva SE
Glance View

Market Cap
619.7m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
10.314 EUR
Undervaluation 63%
Intrinsic Value
Price

See Also

What is Valneva SE's Cash & Cash Equivalents?
Cash & Cash Equivalents
161.3m EUR

Based on the financial report for Jun 30, 2025, Valneva SE's Cash & Cash Equivalents amounts to 161.3m EUR.

What is Valneva SE's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%

Over the last year, the Cash & Cash Equivalents growth was 23%. The average annual Cash & Cash Equivalents growth rates for Valneva SE have been -22% over the past three years , -3% over the past five years , and 14% over the past ten years .

Back to Top